Core Viewpoint - The company, Global Medical (02666), has received approval from the China Securities Regulatory Commission (CSRC) to issue a maximum of 2 billion RMB in domestic perpetual corporate bonds aimed at qualified investors, with a remaining quota of 650 million RMB as of the announcement date [1] Summary by Sections - **Bond Issuance Details** - The bond will be issued in tranches, with the current issuance amount not exceeding 300 million RMB (including 300 million RMB) [1] - The face value of the bond is set at 100 RMB, and the issuance price is also 100 RMB [1] - The expected start date for the offline issuance of this corporate bond is October 24, 2025 [1]

Core Viewpoint - The company, Universal Medical (02666), has received approval from the China Securities Regulatory Commission (CSRC) to issue a maximum of 2 billion RMB in domestic perpetual corporate bonds aimed at qualified investors, with a remaining quota of 650 million RMB as of the announcement date [1] Group 1 - The company's wholly-owned subsidiary, China Universal Leasing Co., Ltd., is the issuer of the bonds [1] - The bonds will be issued in tranches, with the current issuance amount not exceeding 300 million RMB [1] - The face value of the bonds is set at 100 RMB, with an issuance price also at 100 RMB [1] Group 2 - The expected start date for the offline issuance of these corporate bonds is October 24, 2025 [1]

该债券采用分期方式发行，本次债券发行本金总额不超过人民币3亿元(含人民币3亿元)。本期公司债的 基础期限为1年期。本期公司债以和其基础期限相等的期限为1个重定价周期，在约定的基础期限及每个 重定价周期末，发行人有权选择将本次债券期限延长1个重定价周期，或全额兑付本次债券。 格隆汇10月23日丨环球医疗(02666.HK)公告，公司的全资附属公司中国环球租赁有限公司(发行人)已得 到中国证券监督管理委员会批复核准，在中华人民共和国面向合格投资者公开发行本金总额最高达人民 币20亿元的境内可续期公司债，截至本公告日期剩余额度为人民币6.5亿元。 本期公司债附有发行人续期选择权、发行人递延支付利息权、发行人赎回选择权。发行利率在首个周期 内固定不变，并将于截止认购申请时通过簿记建档方式最终厘定，票面利率为初始基准利率加上初始利 差，其後每个周期重置一次，後续周期的票面利率调整为当期基准利率加上初始利差再加300个基点。 发行本期公司债的净额收益将由发行人用作补充运营资金。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發 表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承 擔任何責任。 通用環球醫療集團有限公司 GENERTEC UNIVERSAL MEDICAL GROUP COMPANY LIMITED （於香港註冊成立的有限公司） （股份代號：2666） 有關本公司的全資附屬公司 於中國境內公開發行二零二五年第三期可續期公司債券的公告 本公告乃由通用環球醫療集團有限公司（「本公司」）根據香港聯合交易所有限公司證券上 市規則（「上市規則」）第13.09(2)(a)條及香港法例第571章證券及期貨條例第XIVA部內幕 消息條文（定義見上市規則）作出。 本公司的全資附屬公司中國環球租賃有限公司（「發行人」）已得到中國證券監督管理委員 會（「中證監」）批復核准，在中華人民共和國（「中國」）面向合格投資者公開發行本金 總額最高達人民幣 20 億元的境內可續期公司債，截至本公告日期剩餘額度為人民幣 6.5 億元。 該債券採用分期方式發行，本次債券（「本期公司債」）發行本金總額不超過人民幣 3 ...

Core Viewpoint - Southbound funds increased their holdings in Universal Medical (02666.HK) by 2.468 million shares on October 21, 2025, indicating a positive sentiment towards the company despite some recent fluctuations in holdings [1] Summary by Sections Southbound Fund Activity - Over the past five trading days, there were two days of net reductions in holdings, totaling 259,000 shares [1] - In the last twenty trading days, there were eleven days of net reductions, amounting to 9.7395 million shares [1] - As of now, southbound funds hold 444.5 million shares of Universal Medical, representing 23.51% of the company's total issued ordinary shares [1] Shareholding Changes - On October 21, 2025, total shareholding was 444.5 million shares, with an increase of 2.468 million shares, reflecting a change of 0.56% [2] - On October 20, 2025, total shareholding was 442 million shares, with an increase of 150,500 shares, reflecting a change of 0.03% [2] - On October 17, 2025, total shareholding was 442 million shares, with an increase of 591,500 shares, reflecting a change of 0.13% [2] - On October 16, 2025, total shareholding was 442 million shares, with a decrease of 2.945 million shares, reflecting a change of -0.66% [2] - On October 15, 2025, total shareholding was 445.1 million shares, with a decrease of 524,000 shares, reflecting a change of -0.12% [2] Company Overview - Universal Medical Group Limited, formerly known as Universal Medical Financial and Technical Consulting Services Limited, operates in the healthcare sector in China [2] - The company has two main divisions: the financial services division, which includes direct financing leasing, sale-leaseback, insurance, operating leasing, and consulting services; and the healthcare division, which encompasses healthcare services, hospital operation management, and medical equipment import/export trade [2] - The company primarily conducts its business within mainland China [2]

Core Viewpoint - Southbound funds have reduced their holdings in Universal Medical (02666.HK) by 524,000 shares on October 15, indicating a trend of net selling over recent trading days [1] Group 1: Shareholding Changes - In the last 5 trading days, southbound funds have reduced their holdings on 3 days, with a total net reduction of 4,391,500 shares [1] - Over the past 20 trading days, there have been 12 days of net selling, totaling 10,207,500 shares [1] - As of now, southbound funds hold 445 million shares of Universal Medical, accounting for 23.49% of the company's total issued ordinary shares [1] Group 2: Trading Data - On October 15, 2025, the total shareholding was 445 million shares, with a decrease of 524,000 shares, representing a change of -0.12% [2] - On October 14, 2025, there was an increase of 113,500 shares, a change of 0.03% [2] - On October 13, 2025, a decrease of 1,788,000 shares occurred, reflecting a change of -0.40% [2] - On October 3, 2025, there was an increase of 555,000 shares, a change of 0.12% [2] - On October 2, 2025, a decrease of 2,748,000 shares was noted, representing a change of -0.61% [2] Group 3: Company Overview - Universal Medical Group Co., Ltd. (formerly known as Universal Medical Financial and Technical Consulting Services Co., Ltd.) operates in the healthcare sector in China [2] - The company has two main divisions: financial services, which include direct financing leasing, sale-leaseback, insurance, operating leasing, and consulting services; and healthcare services, which encompass medical health services, hospital operation management, and medical equipment trade [2] - The company primarily conducts its business within mainland China [2]

Core Insights - The article presents a ranking of 33 Hong Kong-listed medical service companies based on their stock price performance as of September 30, 2025, highlighting significant price increases and declines among these companies [1][2]. Group 1: Top Performers - The top performer is Brainstorm Cell Therapeutics (脑动极光-B) with a stock price of HKD 8.58, reflecting a remarkable increase of 166.46% [1]. - MediWound (麦迪卫康) ranks second with a stock price of HKD 1.23, showing a growth of 136.54% [1]. - Yonghe Medical (雍禾医疗) comes in third with a stock price of HKD 2.05, marking a rise of 127.78% [1]. Group 2: Notable Declines - The company with the largest decline is Yimeng Group (云康集团), with a stock price of HKD 1.28, experiencing a drop of 86.15% [1]. - Meizhong Jiahe (美中嘉和) follows with a stock price of HKD 3.20, down by 70.91% [1]. - Another significant decline is seen in Yimeng Sunshine (一昧阳光), which has a stock price of HKD 17.00, down by 76.06% [1]. Group 3: Market Capitalization - Fosun Pharma (复星医药) has the highest market capitalization at HKD 680.48 billion, with a stock price of HKD 25.78 [2]. - Far East Horizon (远东宏信) ranks second with a market cap of HKD 328.32 billion and a stock price of HKD 6.87 [2]. - Global Medical (环球医疗) holds a market cap of HKD 114.82 billion, with a stock price of HKD 6.07 [2].

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 第 2 頁 共 10 頁 v 1.1.1 III.已發行股份及/或庫存股份變動詳情 (A). 股份期權（根據發行人的股份期權計劃） | 截至月份: | 2025年9月30日 | 狀態: 新提交 | | --- | --- | --- | | 致：香港交易及結算所有限公司 | | | | 公司名稱: | 通用環球醫療集團有限公司 | | | 呈交日期: | 2025年10月8日 | | | I. 法定/註冊股本變動 不適用 | | | | 備註： | | | | 因公司註冊成立於香港，故法定股本及註冊股本的概念並不適用。 | | | FF301 第 1 頁 共 10 頁 v 1.1.1 FF301 II. 已發行股份及/或庫存股份變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02666 | 說明 | | | | | | | | | 已發 ...

Investment Rating - The investment rating for the company is "Outperform the Market" [6][27]. Core Viewpoints - The company is focusing on optimizing its revenue and profit structure, with a core business in medical services, supported by financial services and driven by health technology [1][10]. - The company has successfully integrated 65 medical institutions, with a total of 16,168 beds, and is expanding its health technology business [1][10]. - The financial business is showing signs of transformation, with a net interest margin increase and improved asset quality [2][13]. - The company is facing policy pressures in its comprehensive medical services but is advancing health technology acquisitions [3][20]. Summary by Sections Revenue and Profit Structure - For the first half of 2025, the company achieved revenue of 75.81 billion, a year-on-year increase of 15.9%. Medical health business revenue was 49.64 billion, up 27.7%, accounting for 65.5% of total revenue [1][10]. - The annual profit was 13.35 billion, a 6.6% increase, with the medical health business contributing 2.85 billion, a 5.3% increase [1][10]. Financial Business Performance - The financial business generated revenue of 28.51 billion, a 6.9% increase, with a net interest margin of 4.34%, up 0.92 percentage points [2][13]. - The company maintained a good asset quality with a non-performing asset ratio of 0.97% and a provision coverage ratio of 313.87% [2][13]. Comprehensive Medical Services - Comprehensive medical services generated revenue of 42.22 billion, a 15.8% increase, but profit decreased by 14.6% to 2.31 billion [3][20]. - The company reported a total diagnosis volume of approximately 5.09 million, with a surgical volume of 53,000 [3][20]. Health Technology and Acquisitions - The company successfully acquired Beijing Jinxu Yike, with health technology revenue reaching 6.46 billion, a 142.1% increase [3][20]. - The equipment lifecycle management business generated 4.18 billion, up 58.7%, while the smart health business contributed 2.22 billion [3][20]. Investment Outlook - The company is positioned to capitalize on policy opportunities in the healthcare sector, with rapid growth in hospital group business and a focus on health technology and specialized medical services [4][27]. - The projected net profit for 2025-2027 is expected to be 21.21 billion, 21.97 billion, and 22.94 billion, with corresponding PE ratios of 5.0, 4.9, and 4.6 [4][27].

Core Viewpoint - The company reported a strong performance in the first half of 2025, with significant growth in its healthcare segment, driven by its health technology business, while maintaining stability in its financial operations [1] Financial Performance - In the first half of 2025, the company achieved operating revenue of 7.581 billion yuan, a year-on-year increase of 15.9% [1] - The net profit attributable to shareholders was 1.228 billion yuan, reflecting an 8% year-on-year growth [1] Healthcare Segment - The healthcare division generated operating revenue of 4.964 billion yuan, up 27.7% year-on-year, accounting for 65.5% of total revenue [1] - The healthcare segment's net profit was 285 million yuan, a 5.3% increase, representing 21.3% of total net profit [1] - The healthcare business is divided into three segments: - Comprehensive medical services: Revenue of 4.222 billion yuan, a 15.8% increase, but net profit decreased by 14.6% due to DRG payment reform and rising fixed costs [1] - Specialized medical services: Revenue of 130 million yuan, primarily from the newly consolidated Shandong University of Traditional Chinese Medicine Affiliated Eye Hospital [1] - Health technology: Revenue of 646 million yuan, a remarkable 142.1% increase, with equipment management contributing 418 million yuan and a net profit of 48 million yuan, up 45.9% [1] Financial Services - The financial segment reported operating revenue of 2.851 billion yuan, a 6.9% increase, with net profit reaching 1.05 billion yuan, up 7% [1] - As of June 30, 2025, the company had net interest-earning assets of 70.605 billion yuan, with a non-performing asset ratio below 1% and a 30-day overdue rate of 0.9% [1] - The company improved its financing structure and reduced costs, achieving an average cost rate of interest-bearing liabilities of 2.84% [1] Investment Outlook - The company is projected to achieve operating revenues of 14.795 billion yuan, 15.347 billion yuan, and 16.182 billion yuan for 2025-2027, with year-on-year growth rates of 8%, 4%, and 5% respectively [1] - Net profit attributable to shareholders is expected to reach 2.095 billion yuan, 2.230 billion yuan, and 2.356 billion yuan, with growth rates of 3%, 6%, and 6% respectively [1]